anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CONTEXT: In amyotrophic lateral sclerosis (ALS), equal care is important, given that the disease often has complex symptoms at the end of life.
OBJECTIVES: The aim was to study the possible associations between demographic and clinical factors, including age, sex, and frailty, with acute healthcare utilization in the last month of life, measured by emergency room (ER) visits, admissions to acute hospitals and, acute hospitals as place of death, among patients with ALS. A second aim was to study whether receipt of specialized palliative care (SPC) affects above-mentioned healthcare utilization.
METHODS: Observational, retrospective study based on Region Stockholm's administrative data warehouse (VAL) in Sweden. Data were retrieved for 2015-2021 and analyzed with descriptive statistics and logistic regression models.
RESULTS: All deceased patients (n = 448) ≥18 years with ALS were included. The mean age was 70.5 years, 46% were women and 58% had risk of frailty according to Hospital Frailty Risk Score (HFRS). Ninety-nine (22%) were nursing home residents and 49% received SPC. The receipt of SPC in patients with ALS was equal in relation to gender, socio-economic standing, frailty, and age <75 years. Patients ≥75 years, those with dementia and/or residing in nursing homes (NH) were less likely to receive SPC (P = 0.01, P = 0.03 and P = 0.002, respectively). Receipt of SPC reduced ER visits (29% vs. 48%, P < 0.001) and deaths at hospital (12% vs. 48%, P <0.001). Patients who were frail, had a higher risk of ER visits and were more likely to die at an acute hospital setting (P < 0.001 and P = 0.004). NH residents were less likely to have ER visits and to die in hospital (P = 0.002 and P = 0.005).
CONCLUSIONS: The results indicate partly unequal distribution of palliative care, however the actual, individual preferences cannot be deducted from registry studies. All patients with ALS should be offered SPC when needed.
KEY MESSAGE: This register study shows that receipt of SPC in patients with ALS is equal in relation to gender, socioeconomic standing, frailty, and age <75 years, while those ≥75 years, with dementia, or residing in NH were somewhat less likely to receive SPC. Receipt of SPC reduces ER visits and acute hospital admissions.
A variety of modified  Bacillus anthracis  bacteria useful in vaccines are provided. For instance, asporogenic strains of  Bacillus anthracis  are provided. In addition,  Bacillus anthracis  strains attenuated in their ability to repair their nucleic acid, such as in their nucleic acid excision repair ability or recombination repair ability, are provided. Strains expressing an antigen, such as protective antigen, under the control of a heterologous promoter and/or an inducible promoter are also provided.  Bacillus anthracis  bacteria comprising mutations in toxin genes are further provided. Vaccine compositions comprising the bacteria, methods of making the modified strains, and methods of using the vaccines are also provided.
* Initiate ZEMPLAR as an intravenous bolus dose of 0.04 mcg/kg to 0.1 mcg/kg (2.8 mcg to 7 mcg) no more frequently than every other day at any time during dialysis.   

  * Target the maintenance dose of ZEMPLAR to intact parathyroid hormone (PTH) levels within the desired therapeutic range and serum calcium within normal limits.   

  * Monitor serum calcium frequently (e.g., twice weekly) and intact PTH levels every 2 to 4 weeks after initiation of therapy or dose adjustment.   

  * Titrate the dose of ZEMPLAR based on intact PTH (see Table 1). Prior to raising the dose, ensure serum calcium is within normal limits. The maximum daily adult dose is 0.24 mcg/kg.   

  * Suspend or decrease the dose if intact PTH is persistently and abnormally low to reduce the risk of adynamic bone disease [see Warnings and Precautions (5.3)] or if serum calcium is consistently above the normal range to reduce the risk of hypercalcemia [see Warnings and Precautions (5.1)]. If dose suspension is necessary, restart at a reduced dose after laboratory values have normalized.
BACKGROUND: Balance disorders can give rise to sensations of instability, lightheadedness, vertigo, disequilibrium, or syncope, ultimately leading to grave medical, physical, emotional, and societal ramifications. These conditions are highly prevalent among individuals aged 40 and above. Screen time encompasses activities associated with television viewing, video game playing, and non-work-related computer usage. Prolonged screen exposure may engender a spectrum of health issues and even elevate overall mortality rates. However, the available evidence on the potential link between excessive screen time and balance dysfunction remains limited.
AIMS: The primary aim of this study was to explore the possible association between prolonged screen exposure and impaired balance function.
METHODS: This cross-sectional study utilized data from participants who completed a comprehensive questionnaire in the NHANES database between 1999 and 2002, all of whom were aged over 40 and under 85 years. Participants' screen time was categorized into two groups (< 4 h/d and  ≥4 h/d) for subsequent data analysis. Logistic regression, combined with propensity score matching (PSM), was employed to investigate the correlation between screen time and balance disorders.
RESULTS: A total of 5176 participants were enrolled in this study, comprising 2,586 men and 2,590 women, with a prevalence rate of balance disorders at 25.7% (1331/5176). The incidence of balance disorders was found to be significantly higher among individuals who spent 4 hours or more per day on screen time compared to those with less screen time (P<0.001). Multivariate logistic analysis conducted on the unmatched cohort revealed a significant association between screen time and balance disorders, with an odds ratio (OR) 1.8 (95%CI 1.57 ∼ 2.05). These findings remained consistent even after adjusting for confounding factors, yielding an OR 1.43 (95%CI 1.24 ∼ 1.66). Moreover, the association persisted when employing various multivariate analyses such as propensity score matching adjusted model, standardized mortality ratio weighting model and pairwise algorithmic model; all resulting in ORs ranging from 1.38 to 1.43 and p-values < 0.001.
CONCLUSIONS: After controlling for all covariates, screen time (watching TV, playing video games, and using computers outside of work) was associated with balance dysfunction among middle-aged and older adults. This finding may offer a possible idea for the prevention of dizziness and balance disorders. Nevertheless, additional research is imperative to further validate these results.
The use of alcohol in moderation has been associated with reduced mortality rates, reduced risk of cardiovascular disease and reduced risk for type 2 diabetes. However, the effects of alcohol in persons with type 2 diabetes have not yet been defined. Moreover, the possibility of alcohol induced hypoglycemia remains a safety concern. Finally, little is known about the effects of alcohol on plasma lipids in people with diabetes. To address these issues, two substudies are proposed. The first substudy will examine the acute effects of alcohol in the form of wine at supper on postprandial and nocturnal glucose levels. The second substudy will examine the effects of alcohol in the form of wine consumed regularly for one month on plasma lipids.

To test these hypotheses, 20 type 2 diabetics will be studied. In substudy 1, subjects will be admitted to the Clinical Research Center for a two day inpatient stay. Blood samples for plasma glucose and serum insulin will be obtained every two hours from 5:00 pm to 7:00 am. On one day, subjects will recieve 8 ounces of wine with dinner. On the other day, subjects will recieve 8 ounces of fruit juice with dinner. The primary endpoint of substudy 1 will be fasting plasma glucose. In substudy 2, subjects will be asked to consume 4-8 ounces of wine in the evening for one month and to abstain from wine and alcohol containing beverages for one month. Fasting blood samples will be obtained after the month of wine consumption and after the month of abstention from alcohol for measurement of fasting lipids. The primary endpoint of substudy 2 will be fasting HDL cholesterol.
In the south Asian region, delivering non-communicable disease (NCD) prevention and control services through existing primary health-care (PHC) facilities is urgently required yet currently challenging. As the first point of contact with the health-care system, PHC offers an ideal window for prevention and continuity of care over the life course, yet the implementation of PHC to address NCDs is insufficient. This review considers evidence from five south Asian countries to derive policy-relevant recommendations for designing integrated PHC systems that include NCD care. Findings reveal high political commitment but poor multisectoral engagement and health systems preparedness for tackling chronic diseases at the PHC level. There is a shortage of skilled human resources, requisite infrastructure, essential NCD medicines and technologies, and dedicated financing. Although innovations supporting integrated interventions exist, such as innovations focusing on community-centric approaches, scaling up remains problematic. To deliver NCD services sustainably, governments must aim for increased financing and a redesign of PHC service.
The basic principle of bromocriptine mesylate tablets therapy is to initiate treatment at a low dosage and, on an individual basis, increase the daily dosage slowly until a maximum therapeutic response is achieved. The dosage of levodopa during this introductory period should be maintained, if possible. The initial dose of bromocriptine mesylate is half of a 2.5 mg tablet twice daily with meals. Assessments are advised at 2-week intervals during dosage titration to ensure that the lowest dosage producing an optimal therapeutic response is not exceeded. If necessary, the dosage may be increased every 14 to 28 days by 2.5 mg/day with meals. Should it be advisable to reduce the dosage of levodopa because of adverse reactions, the daily dosage of bromocriptine mesylate, if increased, should be accomplished gradually in small (2.5 mg) increments.

The safety of bromocriptine mesylate has not been demonstrated in dosages exceeding 100 mg/day.
<P>PROBLEM TO BE SOLVED: To obtain a new angiogenesis regulator and to provide a method for screening the regulator.  <P>SOLUTION: This angiogenesis regulator comprises a substance regulating expression or function of Ovo2 (a transcription regulator) as an active ingredient. The method for screening a substance having therapeutic activity against diseases involving angiogenesis comprises screening the substance regulating expression or activity of Ovo2. An Ovo2 function-deleted nonhuman animal is obtained by introducing variation into an Ovo2 gene. A new Ovo2 gene is also provided.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
NEW MATERIAL:A monoclonal antibody having human placenta ferritin as immunizing source, reactive to the ferritin of the tissue of human liver, placenta and pancreas and to the serum ferritin and having iron metabolizing activity. USE:Reagent for the determination of serum ferritin. PREPARATION:For example, human placenta ferritin is infused together with complete Freund's adjuvant into the abdominal cavity of a BALB/C mouse, and the spleen cells are collected after 3 days from the final immunization. The cell is subjected to cell fusion with mouse myeloma cell using polyethylene glycol, etc., and cultured in HAT medium to obtain hybrid 2. The hybrid is screened, and monoclonized by critical dilution method, etc., to obtain a monoclonal antibody-producing hybrid 2. The objective monoclonal antibody can be produced by culturing the hybrid 2 in a medium.
During coronary artery bypass grafting (CABG), the surgical procedure, particularly the manipulation of the major arteries of the heart, induces a significant inflammatory state that may compromise platelet function to the extent that platelet transfusion is required. Given stored platelets as a major source of biological mediators, this study investigates the effects of platelet transfusion on the major pro-aggregatory, pro-inflammatory and immunomodulatory markers of platelets. Platelets from 20 patients, 10 who received platelet transfusion and 10 without, were subjected to flow cytometery where P-selectin and CD40 ligand (CD40L) expressions and PAC-1 binding (activation-specific anti GPIIb/GPIIIa antibody) analysed at five-time points of 24 h before surgery, immediately, 2 h, 24 h and 1 week after surgery. Analysis of intra-platelet transforming growth factor-beta-1 (TGF-β1) was also conducted using western blotting. Patients with platelet transfusion showed increased levels of P-selectin, CD40L and intra-platelet TGF-β1 2-h after surgery compared to those without transfusion (p < 0.05). PAC-1 binding was increased 24 h after surgery in transfused patients (p < 0.05). Given the significant post-transfusion elevation of platelet TGF-β1, P-sel/CD40L reduction in transfused patients a week after was of much interest. This study showed for the first time the significant effects of platelet transfusion on the pro-inflammatory, pro-aggeregatory and immunomodulatory state of platelets in CABG patients, which manifested with immediate, midterm and delayed consequences. While the increased pro-inflammatory conditions manifested as an immediate effect of platelet transfusion, the pro-aggregatory circumstances emerged 24 h post-transfusion. A week after surgery, attenuations of pro-inflammatory markers of platelets in transfused patients were shown, which might be due to the immunomodulatory effects of TGF-β1.
After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer.
BACKGROUND: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia.
METHODS: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors.
RESULTS: Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications.
CONCLUSIONS: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.
PURPOSE:To obtain the title tea good in both color/gloss and perfume, retaining stabilized quality for a long period, by such processes that the leaves of Sasa albo-marginata are dipped into water, sterilized with warm water, cut into pieces and introduced into a drying chamber where said pieces are dried in such a state as to be in a steam bath to a specified condition. CONSTITUTION:Firstly, the leaves of Sasa albo-marginata are collected using e.g. a large-volume container so as not to be warmed during their collection work. Secondly, the collected leaves are immediately dipped into cold water and transferred to warm water at 80-90 deg.C where said leaves are immersed for 3min to carry out sterilization. Thirdly, the resultant leaves are dipped into cold water again followed by cutting into pieces 1-5mm in size. hence, these pieces with water left to adhere are introduced into a drying chamber where said pieces are dried with an airflow at 80-90 deg.C in such a state as to be in a steam bath to bring the water content to 5wt.%. At this point, the hot airflow is stopped feeding and a cold airflow is fed to bring the water content of said leaf pieces to 0%, thus obtaining the objective tea.
The assembly and communications of a generic reporting engine for offering clinical structured reports using the Internet in an encrypted manner is provided. This method of rendering structured reports employs a DICOM Structured Reporting (SR) software database engine that maps clinical report data into a clinical structured reporting data format using a Report Editor Plug-in which is responsible for constructing the report editor GUI, for parsing the DICOM SR report to show it in the Report Editor window and to store the report content created in the GUI to the DICOM SR format. The report engine can be configured with any number of software plug-ins, so totally different ways of acquiring user input may be implemented. The current invention implements the software plug-ins using a tree-like GUI. The current implementation of this plug-in is based on DICOM SR pull model which is considered more feasible to control its presentation form, but the reporting engine allows for implementation of push model report editor plug-ins. Nothing in this novel approach to clinical reporting prevents the application from implementing a report editor from editing any DICOM SR report in a generic way, like recognizing a report from voice dictation. The Reporting Engine of the present invention provides a way for the plug-ins to recognize if they are able to open the report or not. It can be done either by software plug-ins' report introspection or the process is configurable in the using the invention's reporting engine. The novel reporting engine provides a way of configuring a Report Editor Plug-in, so with one generic plug-in one may have many report templates just by configuring the plug-in. The currently implemented plug-in uses this possibility to define the report definition and GUI tree in a configuration file.
The present invention provides a method for preparing an antler polypeptide, which comprises: antlers are cut into small blocks, and the antler blocks are flushed by cool water until the antler blocks have no blood color; the antler blocks are pulverized and are ground into homogenate by colloid; homogenate liquid is continuously added, and ultrasonic treatment is carried out; supernatant liquid is taken by centrifugation; ethanol is added to the supernatant liquid; the supernatant liquid is placed and stirred, and is then centrifugated; supernatant liquid is obtained to be evaporated in a rotary mode; the supernatant liquid is frozen and dried; and the antler polypeptide is obtained. The method discloses medicine with the antler polypeptide obtained by the preparation method as active ingredients, and the medicine contains at least one kind of carrier acceptable to pharmacy; for example, the medicine can be compound antler polypeptide mouth cavity spraying preparations. The antler polypeptide extracted by the biochemical method maintains the original activity. The antler polypeptide is matched with GHRP and is prepared into oral cavity spraying preparations directly entering human bodies through oral mucosa so as to take effect. The method overcomes the negligence and the waste of antler polypeptides by former antler utilization methods, and increases the utilization efficiency of antlers. The method provides technology and products for solving the problems of GH hyposecretion of middle-aged people and old people.
We aimed to analyse the association between processed food consumption and the risk of non-communicable diseases (NCDs) in South Africa. In this empirical study, we analysed nationally representative secondary data obtained from the South African Demographic and Health Survey (SADHS) VII. The survey included 13,288 occupied households, of which 11,083 were interviewed. In the interviewed households, 12,717 eligible adults aged 15 and older were identified and 10,336 were successfully interviewed. The study included four processed food groups (i.e. fried foods, takeaway foods/fast foods, salty snacks/packed chips, and processed meats) and eight NCDs (i.e. hypertension, cardiac arrest, cancer, stroke, hypercholesterolaemia, diabetes, chronic bronchitis, and asthma). As per the logistic regression results following adjustment, none of the disease states showed association with all four processed food groups. However, at least three processed food groups showed a significant positive association with hypertension, cardiac arrest, and diabetes. Two processed food groups showed significant positive association with stroke, and chronic bronchitis; one with hypercholesterolaemia and asthma; and cancer was not associated with any food groups. Processed meat and salted snacks/packed chips were each associated with five chronic conditions. In summary, we found that the consumption of any of the processed food groups increased the risk of NCDs in the South African population. Enabling policy and regulatory efforts in the production and distribution of processed foods, combined with improved awareness among the population need to be prioritised for immediate action. Facilitating the populations to choose traditional healthy diets would be a sustainable strategy for the prevention of NCDs.
Ca-DTPA is associated with depletion of endogenous trace metals (e.g., zinc, magnesium, manganese). The magnitude of depletion increases with split daily dosing, with increasing dose, and with increased treatment duration. [See Clinical Pharmacology (12.3)] Only a single initial dose of Ca-DTPA is recommended. Use Zn-DTPA if additional chelation therapy is indicated (See Zn-DTPA labeling). If Zn-DTPA is not available, chelation therapy may continue with Ca-DTPA but give mineral supplements containing zinc concomitantly, as appropriate.

Monitor serum zinc levels, electrolytes and blood cell counts during Ca-DTPA or Zn-DTPA therapy. Give mineral or vitamin plus mineral supplements that contain zinc as appropriate. [See Dosage and Administration (2.4)]